Pharmaceutical Formulations Using 3D Printing: Advances and Challenges

Over the past decade, the integration of three-dimensional (3D) printing into pharmaceutical sciences has emerged as a transformative approach for drug development and personalized medicine. Initially developed for rapid industrial prototyping, 3D printing has evolved into a versatile tool capable of fabricating customized, complex, and multi-functional drug delivery systems. The FDA’s 2015 approval of Spritam (levetiracetam), the world’s first 3D-printed oral drug, marked a pivotal moment, validating the clinical potential of additive manufacturing in the pharmaceutical sector. 3D printing enables the layer-by-layer construction of dosage forms with intricate geometries and tailored drug release kinetics. Techniques such as fused deposition modelling (FDM), inkjet printing, stereolithography (SLA), and semi-solid extrusion (SSE) have been adapted for pharmaceutical use, offering unique benefits regarding material compatibility, resolution, and scalability. These innovations have enabled the development of orodispersible tablets, polypills, pediatric and geriatric formulations, and implantable drug systems. Recent advances emphasize drug-excipient compatibility, print resolution, reproducibility, and overcoming thermal stability and post-processing challenges. The incorporation of AI-based formulation modeling, 4D printing (dynamic structures), and bioprinting of tissues and scaffolds marks the frontier of pharmaceutical innovation. Challenges include scaling production, ensuring GMP compliance, and validating digital workflows. Regulatory bodies such as the FDA and EMA are actively working on integrating these technologies within regulatory frameworks. In conclusion, the past ten years have highlighted 3D printing’s potential to revolutionize pharmaceutical manufacturing, particularly in personalized medicine. As technological, regulatory, and material science barriers are addressed, 3D printing is poised to become integral to the pharmaceutical industry’s future.